Between the two phase-3 Clevudine trials—one for e+ and one for e- patients—there are four arms in all: two Clevudine arms and two Hepsera control) arms. Among these four arms, only the Hepsera arm in the e- trial does not include a stoppage of treatment at week 72 to test for SVR.
Q: Why is this arm different from all other arms?
p.s. This makes four posts in a row about VRUS! I better find something else to post about
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”